Results 91 to 100 of about 59,839 (262)

Evaluation of the KEMRI Hep-cell II test kit for detection of hepatitis B surface antigens in Tanzania [PDF]

open access: yes, 2013
Hepatitis B surface antigen (HBsAg) is one of the most important serological markers used to diagnose acute and chronic hepatitis B infection. The objective of the current evaluation was to assess the operational characteristics of the Kenya Medical ...
NGOWI, PROSPER H.   +4 more
core   +1 more source

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi   +8 more
wiley   +1 more source

A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Cirrhosis patients with untreated HBV in Ethiopia exhibit a distinct immune profile marked by depletion of NK cells, B cells, and T cells, alongside an expanded CD38+HLA‐DR+ CD8 T‐cell population. ABSTRACT Background and Aims The immune cell phenotype of African patients living with chronic hepatitis B virus (HBV) infection is rarely described, despite
Julia MacLeod   +9 more
wiley   +1 more source

Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins   +6 more
wiley   +1 more source

Antiviral Therapy and Post‐Resection Outcomes in Patients With Hepatitis B Virus‐Related Hepatocellular Carcinoma

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In 902 patients with HBV‐related HCC undergoing curative resection, antiviral regimens (ETV, TDF, TAF) showed comparable recurrence‐free survival. However, TDF was independently associated with improved overall survival compared with ETV. ABSTRACT Background & Aims The comparative outcomes of entecavir (ETV), tenofovir disoproxil fumarate (TDF), and ...
Jaehong Jeong   +10 more
wiley   +1 more source

Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection [PDF]

open access: yes, 2009
Autoimmune hepatitis (AIH) is a chronic liver disease of unknown etiology, characterized by a loss of tolerance against hepatocytes leading to the progressive destruction of hepatic parenchyma and cirrhosis. Clinical signs for AIH are interface hepatitis
Holdener, Martin
core  

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

The transmembrane domain of the adenovirus E3/19K protein acts as an ER retention signal and contributes to intracellular sequestration of MHC class I molecules [PDF]

open access: yes, 2013
The human adenovirus E3/19K-protein is a type-I transmembrane glycoprotein of the endoplasmic reticulum (ER) that abrogates cell-surface transport of MHC class-I (MHC-I) and MICA/B-molecules.
Ruszics, Zsolt   +3 more
core  

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy